BOSTON--(BUSINESS WIRE)--Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that members of its management team will participate in the following upcoming investor conferences in March:
- Leerink Partners Global Healthcare Conference 2025
- The Seaport management team was invited to participate in one-on-one meetings at the conference on March 10-12th in Miami, FL.
- Stifel 2025 Virtual CNS Forum
- The Seaport management was invited to present on Wednesday, March 19th at 2:00 – 2:25pm EDT. The live and archived webcast will be available under the Events section of the Company’s website at https://seaporttx.com/news-papers/.
About Seaport Therapeutics
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary GlyphTM technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit www.seaporttx.com.
Contacts
Public Relations
publicrelations@seaporttx.com
Investor Relations
ir@seaporttx.com
